In August 2025, Dren Bio announced a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.

谷歌研究团队提出了一种新型的隐私保护合成数据生成算法CTCL，能够在保证隐私的前提下自动生成高质量的合成数据。这项技术不仅减少了计算负担，还提高了数据生成的质量和效率。 近日，谷歌研究人员在ICML 2025会议上展示了他们的最新成果——一种名为CTCL（Data Synthesis with ConTrollability and ...

Download Cutaneous T-cell Lymphoma Sample report to know in detail about the Cutaneous T-cell Lymphoma treatment market @ Cutaneous T-cell Lymphoma Therapeutic Assessment Table of Content 1.

新泽西州 - Citius Oncology, Inc. (NASDAQ: CTOR )周五宣布，该公司已实施一个人工智能平台，以增强其商业运营，为预期推出的皮肤T细胞淋巴瘤 (CTCL)治疗药物LYMPHIR做准备。母公司Citius Pharmaceuticals (NASDAQ: CTXR )目前交易价格为$1.23，根据 InvestingPro ...

DelveInsight's HDAC Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) is making strides with its HyBryte (TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that ...

Click here to view the custom infographic of the Soligenix Inc. editorial. Clickhere  to view the custom infographic of the Soligenix Inc. editorial. Chronic rare diseases are emerging as a major ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...

Markets regulator Securities and Exchange Board of India (SEBI) has imposed a penalty of Rs2 lakh on SMC Global Securities ...

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands ...